An acidic oligopeptide displayed on AAV2 improves axial muscle tropism after systemic delivery

Genetic Vaccines and Therapy

Volumn 10, Issue , 2012, Pages

  Lee, Ni Chung ^a   Falk, Darin J ^b   Byrne, Barry J ^b,c   Conlon, Thomas J ^c   Clement, Nathalie ^c   Porvasnik, Stacy ^b   Jorgensen, Marda L ^b   Potter, Mark ^c   Erger, Kirsten E ^c   Watson, Rachael ^c   Ghivizzani, Steven C ^c   Chiu, Hung Chuan ^a   Chien, Yin Hsiu ^a   Hwu, Wuh Liang ^a,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acidic oligopeptide; Adeno associated virus; L aspartic acid; Tropism

Indexed keywords

AMINO ACID; ASPARTIC ACID; ASPARTIC ACID PARVOVIRUS VECTOR 2; OLIGOPEPTIDE; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MOUSE; MUSCLE DISEASE; NEWBORN; NONHUMAN; VIRAL GENE THERAPY;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MIRIDAE; MUS;

EID: 84862247520     PISSN: None     EISSN: 14790556     Source Type: Journal    
DOI: 10.1186/1479-0556-10-3     Document Type: Article

References (22)

1. Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 2008, 15:858-863. 10.1038/gt.2008.68, 18418415.
2. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996, 70:8098-8108. 190884, 8892935.
3. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999, 6:1574-1583. 10.1038/sj.gt.3300994, 10490767.
4. Hu C, Busuttil RW, Lipshutz GS. RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy. J Gene Med 2010, 12:766-778. 10.1002/jgm.1496, 2948027, 20821747.
5. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008, 16:1073-1080. 10.1038/mt.2008.76, 18414476.
6. Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, Ertl HC, Muruve DA, Lee B, Herzog RW. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 2011, 117:6459-6468. 10.1182/blood-2010-10-314518, 3123017, 21474674.
7. Hasbrouck NC, High KA. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects. Gene Ther 2008, 15:870-875. 10.1038/gt.2008.71, 18432276.
8. White AF, Mazur M, Sorscher EJ, Zinn KR, Ponnazhagan S. Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells. Hum Gene Ther 2008, 19:1407-1414. 10.1089/hum.2008.117, 18778196.
9. Bell CL, Vandenberghe LH, Bell P, Limberis MP, Gao GP, Van Vliet K, Agbandje-McKenna M, Wilson JM. The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J Clin Invest 2011, 121:2427-2435. 10.1172/JCI57367, 3104778, 21576824.
10. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998, 72:1438-1445. 124624, 9445046.
11. Opie SR, Warrington KH, Agbandje-McKenna M, Zolotukhin S, Muzyczka N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 2003, 77:6995-7006. 10.1128/JVI.77.12.6995-7006.2003, 156206, 12768018.
12. Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T, Flotte T, Muzyczka N. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000, 74:8635-8647. 10.1128/JVI.74.18.8635-8647.2000, 102071, 10954565.
13. Yu CY, Yuan Z, Cao Z, Wang B, Qiao C, Li J, Xiao X. A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther 2009, 16:953-962. 10.1038/gt.2009.59, 2726895, 19474807.
14. Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, Hacker U, Thrasher AJ, Ali RR, Hallek M, Baker AH. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 2001, 4:174-181. 10.1006/mthe.2001.0424, 11545607.
15. Grifman M, Trepel M, Speece P, Gilbert LB, Arap W, Pasqualini R, Weitzman MD. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 2001, 3:964-975. 10.1006/mthe.2001.0345, 11407911.
16. Kasugai S, Fujisawa R, Waki Y, Miyamoto K, Ohya K. Selective drug delivery system to bone: small peptide (Asp)6 conjugation. J Bone Miner Res 2000, 15:936-943.
17. Nishioka T, Tomatsu S, Gutierrez MA, Miyamoto K, Trandafirescu GG, Lopez PL, Grubb JH, Kanai R, Kobayashi H, Yamaguchi S, et al. Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol Genet Metab 2006, 88:244-255. 10.1016/j.ymgme.2006.02.012, 2587042, 16616566.
18. Tomatsu S, Montano AM, Dung VC, Ohashi A, Oikawa H, Oguma T, Orii T, Barrera L, Sly WS. Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome. Mol Ther 2010, 18:1094-1102. 10.1038/mt.2010.32, 2889747, 20332769.
19. Matsumoto T, Miyake K, Yamamoto S, Orimo H, Miyake N, Odagaki Y, Adachi K, Iijima O, Narisawa S, Millan JL, et al. Rescue of severe infantile hypophosphatasia mice by AAV-mediated sustained expression of soluble alkaline phosphatase. Hum Gene Ther 2011, 22(11):1355-1364. 10.1089/hum.2010.210, 21388343.
20. Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ, Chiodo VA, Phillipsberg T, Muzyczka N, Hauswirth WW, et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002, 28:158-167. 10.1016/S1046-2023(02)00220-7, 12413414.
21. Lock M, McGorray S, Auricchio A, Ayuso E, Beecham EJ, Blouin-Tavel V, Bosch F, Bose M, Byrne BJ, Caton T, et al. Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther 2010, 21:1273-1285. 10.1089/hum.2009.223, 2957240, 20486768.
22. Saguil A. Evaluation of the patient with muscle weakness. Am Fam Physician 2005, 71:1327-1336.